Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2018

View Archived Issues

Researchers present gene therapy for methamphetamine-induced inflammation

Patient recruitment ongoing in phase II/III trial of relatlimab plus nivolumab in melanoma

Duke University patents mitochondrial antiviral-signaling protein compositions

Orion Pharma enrolls participants in first-in-human study of ODM-208

Achaogen receives funds to support development of aminoglycoside antibiotics

Positive outcome of interim analysis of STRIDE-1 study of AXS-05

Asavi presents inhibitors of HCV NS5B polymerase, HBV DNA polimerase and HIV-1 reverse transcriptase

Novel STAT5 inhibitors synthesized at Freie Universitaet Berlin

AbbVie, Galapagos discover new CFTR modulators

Oppilotech awarded grant for bacterial cell wall model

U.S. Department of Health & Human Services, Codagenix patent novel RSV vaccine

Amgen profiles pipeline progress of first quarter 2018

Venglustat shows favorable safety and tolerability and biologic activity in healthy volunteers

New phase II trial studies ISA-101 with utomilumab for HPV16-positive oropharyngeal cancer

FDA grants breakthrough therapy designation to OMS-721 for HSCT thrombotic microangiopathy

Vertex initiates phase III studies of VX-445, tezacaftor and ivacaftor in cystic fibrosis

DNAJC15 expression linked to NAFLD pathogenesis

Onxeo initiates phase I study of intravenous AsiDNA in advanced solid cancers

Neuraltus' NP-001 safe and well tolerated but does not slow disease progression in ALS

Lupus Research Alliance collaborates with Bristol-Myers Squibb to study BMS-986165 for lupus

ThromboGenics initiates phase II trial of THR-317 with Lucentis for DME

Proteus Digital Health expands digital medicine pipeline into oncology

Fujirebio, Janssen enter agreement to develop amyloid beta 42/40 ratio assay

Tusk Therapeutics' TSK-011010 described as best-in-class anti-CD38 antibody

MSD applies to expand approval of Keytruda in Japan

ZED-1227 begins phase IIa study in patients with celiac disease

Bristol-Myers Squibb updates key milestones of first quarter 2018

Ono files for Japanese approval of metyrosine for patients with pheochromocytoma

Chugai files in Japan for Hemlibra for hemophilia A without inhibitors and to extend dosing interval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...